UA124939C2 - СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ - Google Patents

СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ

Info

Publication number
UA124939C2
UA124939C2 UAA201909190A UAA201909190A UA124939C2 UA 124939 C2 UA124939 C2 UA 124939C2 UA A201909190 A UAA201909190 A UA A201909190A UA A201909190 A UAA201909190 A UA A201909190A UA 124939 C2 UA124939 C2 UA 124939C2
Authority
UA
Ukraine
Prior art keywords
durd
desoxyuridine
human subject
plasma concentration
increasing plasma
Prior art date
Application number
UAA201909190A
Other languages
English (en)
Inventor
Йоран У. Карлссон
Бенгт ГУСТАВССОН
Елізабет Одін
Элизабет Один
Івонн Веттергрен
Ивонн Веттергрен
Андерс Ведін
Андерс ВЕДИН
Original Assignee
Ісофол Медікал Ав
Исофол Медикал Ав
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ісофол Медікал Ав, Исофол Медикал Ав filed Critical Ісофол Медікал Ав
Publication of UA124939C2 publication Critical patent/UA124939C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Винахід стосується способу збільшення концентрації дезоксіуридину (dUrd) в плазмі у суб’єкта-людини, де вказаний суб’єкт-людина страждає на колоректальний рак, який включає введення 400 або 500 мг/м2 5-фторурацилу (5-ФУ) внутрішньовенно як болюсної ін’єкції суб’єкту-людині та введення 30, 60, 120 або 240 мг/м2 [6R]-5,10-метилентетрагідрофолату (6R-МТГФ) внутрішньовенно у вигляді двох болюсних ін’єкцій вказаному суб’єкту-людині.
UAA201909190A 2017-02-14 2018-02-09 СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ UA124939C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458868P 2017-02-14 2017-02-14
PCT/IB2018/000206 WO2018150264A1 (en) 2017-02-14 2018-02-09 METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION

Publications (1)

Publication Number Publication Date
UA124939C2 true UA124939C2 (uk) 2021-12-15

Family

ID=62002152

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201909190A UA124939C2 (uk) 2017-02-14 2018-02-09 СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ

Country Status (16)

Country Link
US (3) US10292984B2 (uk)
EP (2) EP3582812A1 (uk)
JP (2) JP7122256B2 (uk)
KR (1) KR20190112711A (uk)
CN (1) CN110430896A (uk)
AR (1) AR110800A1 (uk)
AU (1) AU2018220861B2 (uk)
BR (1) BR112019016668A2 (uk)
CA (1) CA3053293C (uk)
IL (1) IL268439B2 (uk)
MX (1) MX386434B (uk)
PH (1) PH12019501893A1 (uk)
SG (1) SG11201907442UA (uk)
TW (1) TWI803480B (uk)
UA (1) UA124939C2 (uk)
WO (1) WO2018150264A1 (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3002774B2 (ja) 1996-11-19 2000-01-24 株式会社成形技研 暗渠パイプとその製造装置
EP3446704A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2018150264A1 (en) * 2017-02-14 2018-08-23 Isofol Medical Ab METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
WO2023046305A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
WO2023046307A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
WO2023046304A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
CN114910579B (zh) * 2022-04-13 2023-04-07 中国药科大学 血清中脱氧尿苷定量测定方法及在心肌梗死诊断中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20070019725A (ko) 2004-04-02 2007-02-15 어드벤트륵스 파마슈티칼스, 인크. 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도
CN1942189A (zh) * 2004-04-02 2007-04-04 阿德文特克斯药物有限公司 5,10－亚甲基四氢叶酸在癌症治疗中的用途
JP2007531728A (ja) * 2004-04-02 2007-11-08 アドベントルクス ファーマシューティカルズ， インコーポレイテッド 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用
WO2007064968A2 (en) 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
WO2008109349A1 (en) 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
RU2482496C2 (ru) 2008-09-26 2013-05-20 Эститю Де Кансероложи Де Л'Вест Оптимизация индивидуальных доз 5-фторурацила при режиме folfox
CA2796205A1 (en) 2010-04-15 2011-10-20 Vegenics Pty Limited Combination treatment with vegf-c antagonists
EP2617422A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
EP3446703A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3305318A1 (en) 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
WO2018150264A1 (en) * 2017-02-14 2018-08-23 Isofol Medical Ab METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION

Also Published As

Publication number Publication date
US20180289711A1 (en) 2018-10-11
MX2019009610A (es) 2020-01-14
CA3053293C (en) 2023-01-03
JP7122256B2 (ja) 2022-08-19
EP3582812A1 (en) 2019-12-25
IL268439B2 (en) 2024-04-01
AR110800A1 (es) 2019-05-02
AU2018220861B2 (en) 2021-08-19
EP3848036A2 (en) 2021-07-14
AU2018220861A1 (en) 2019-09-05
EP3848036A3 (en) 2021-08-18
SG11201907442UA (en) 2019-09-27
KR20190112711A (ko) 2019-10-07
US10292984B2 (en) 2019-05-21
CA3053293A1 (en) 2018-08-23
JP2021008510A (ja) 2021-01-28
TW201832766A (zh) 2018-09-16
NZ756408A (en) 2024-01-26
IL268439B1 (en) 2023-12-01
BR112019016668A2 (pt) 2020-04-07
PH12019501893A1 (en) 2019-10-21
US20200330468A1 (en) 2020-10-22
CN110430896A (zh) 2019-11-08
MX386434B (es) 2025-03-18
US11389452B2 (en) 2022-07-19
US10639311B2 (en) 2020-05-05
WO2018150264A1 (en) 2018-08-23
TWI803480B (zh) 2023-06-01
IL268439A (en) 2019-09-26
US20190240224A1 (en) 2019-08-08
JP2020505316A (ja) 2020-02-20
RU2019126648A (ru) 2021-03-16
RU2019126648A3 (uk) 2021-03-16

Similar Documents

Publication Publication Date Title
CY1125436T1 (el) Αναστολεις dna-pk
JOP20200115A1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
JOP20190272B1 (ar) مثبطات kras g12c وطرق لاستخدامها
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX389672B (es) Inhibidores de ssao de aminopirimidina
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201591509A1 (ru) Ингибиторы cdc7
EA201791095A1 (ru) Способ лечения рака
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201691421A1 (ru) Гетероарилы и их применение
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX381994B (es) Inhibidor de janus quinasa.
PH12019501893A1 (en) Methods for increasing blood plasma 2`-deoxyuridine (durd) and thymidylate synthase inhibition
MX384833B (es) Inhibidores de tirosina quinasa de bruton
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).